Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study
Virendra Rambiritch,1 Breminand Maharaj,2 Poobalan Naidoo3 1Biomedical Research Ethics Committee, University of Kwazulu-Natal, Durban, KwaZulu-Natal, South Africa; 2Department of Therapeutics and Medicines Management, University of Kwazulu-Natal, Durban, KwaZulu-Natal, South Africa; 3Boehringer-Ing...
Guardado en:
Autores principales: | Rambiritch V, Maharaj B, Naidoo P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/afefd090cba3450398af0fbe2ce5d64a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects
por: Rambiritch V, et al.
Publicado: (2016) -
Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects
por: Rambiritch V, et al.
Publicado: (2016) -
Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.
por: Nathan W Cummins, et al.
Publicado: (2021) -
An Investigator-Initiated, Prospective, Single-Center, Open-Label Clinical Study to Evaluate Safety and Performance of Intra-Articular Hyaluronic Acid (IA-HA) (Biovisc Ortho) in Patients with Osteoarthritis (OA) of the Knee
por: Gupta A, et al.
Publicado: (2021) -
Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
por: Hendrikx JJMA, et al.
Publicado: (2020)